Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 22 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

6Total
Not Applicable (3)
P 2 (2)
P 3 (1)

Trial Status

Unknown7
Recruiting6
Completed5
Active Not Recruiting3
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (22)

Showing 20 of 20 trials
NCT07485413Active Not Recruiting

Looking for VUS to Confirm Dominant Wolfram-like Syndrome Instead of Recessive Wolfram Syndrome

NCT07085533Recruiting

Natural History Study of Inherited Retinal Diseases

NCT03857594Active Not Recruiting

Integrative Sequencing In Germline and Hereditary Tumours

NCT03702309Recruiting

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

NCT05848271Recruiting

Natural History Study of Patients with HPDL Mutations

NCT03246841Not ApplicableActive Not Recruiting

Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.

NCT06563999Phase 2Recruiting

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

NCT06584994Enrolling By Invitation

Investigating the Role of Genetics in Disease Predisposition

NCT05446155Recruiting

BioMEL- Diagnostic and Prognostic Factors in Melanoma.

NCT05954442Phase 3Recruiting

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

NCT05162508Unknown

Impact of COVID-19 SARS-CoV-2 Variability in ICU Hospitalized Patients With Severe Disease

NCT05311709Phase 2Unknown

Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities

NCT05864937CompletedPrimary

C677T Methylenetetrahydrofolate Reductase Mutation

NCT04983628Unknown

Molecular Profiling in Prostate Cancer

NCT02884063Completed

Utilizing Free DNA in Embryo Culture for PGT

NCT04708639Unknown

Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients

NCT03902353Not ApplicableUnknownPrimary

Screening of Pulmonary Veino Occlusive Disease in Heterozygous EIF2AK4 Mutation Carriers

NCT04068961Completed

New Strategies of Genetic Study of Patients With Oculocutaneous Albinism

NCT03786575Not ApplicableUnknown

Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer

NCT02612350CompletedPrimary

Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease

Scroll to load more

Research Network

Activity Timeline